A citation-based method for searching scientific literature

Omkar U Kawalekar, Roddy S O'Connor, Joseph A Fraietta, Lili Guo, Shannon E McGettigan, Avery D Posey, Prachi R Patel, Sonia Guedan, John Scholler, Brian Keith, Nathaniel W Snyder, Ian A Blair, Michael C Milone, Carl H June. Immunity 2016
Times Cited: 409



Leonid Cherkassky, Aurore Morello, Jonathan Villena-Vargas, Yang Feng, Dimiter S Dimitrov, David R Jones, Michel Sadelain, Prasad S Adusumilli. J Clin Invest 2016
Times Cited: 422




List of shared articles



Times cited


Clinical CAR-T Cell and Oncolytic Virotherapy for Cancer Treatment.
Norihiro Watanabe, Mary Kathryn McKenna, Amanda Rosewell Shaw, Masataka Suzuki. Mol Ther 2021
7

Anti-CD19 CAR-T cells: Digging in the dark side of the golden therapy.
Stella Bouziana, Dimitrios Bouzianas. Crit Rev Oncol Hematol 2021
2

Genetic engineering of T cells for immunotherapy.
Gavin I Ellis, Neil C Sheppard, James L Riley. Nat Rev Genet 2021
3

Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy.
Ying Gong, Roel G J Klein Wolterink, Jianxiang Wang, Gerard M J Bos, Wilfred T V Germeraad. J Hematol Oncol 2021
2

CAR T-cell therapy for pleural mesothelioma: Rationale, preclinical development, and clinical trials.
Navin K Chintala, David Restle, Hue Quach, Jasmeen Saini, Rebecca Bellis, Michael Offin, Jason Beattie, Prasad S Adusumilli. Lung Cancer 2021
1

A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains.
Kathryn M Cappell, James N Kochenderfer. Nat Rev Clin Oncol 2021
3

CAR T-cell therapy in mature lymphoid malignancies: clinical opportunities and challenges.
Mayur Narkhede, Amitkumar Mehta, Stephen M Ansell, Gaurav Goyal. Ann Transl Med 2021
0

Mitochondria as Playmakers of CAR T-cell Fate and Longevity.
Hosein Rostamian, Mohammad Khakpoor-Koosheh, Keyvan Fallah-Mehrjardi, Hamid R Mirzaei, Christine E Brown. Cancer Immunol Res 2021
0

Determinants of response and mechanisms of resistance of CAR T-cell therapy in multiple myeloma.
Niels W C J van de Donk, Maria Themeli, Saad Z Usmani. Blood Cancer Discov 2021
1

Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function.
Alexander I Salter, Anusha Rajan, Jacob J Kennedy, Richard G Ivey, Sarah A Shelby, Isabel Leung, Megan L Templeton, Vishaka Muhunthan, Valentin Voillet, Daniel Sommermeyer,[...]. Sci Signal 2021
0

Clinical and Product Features Associated with Outcome of DLBCL Patients to CD19-Targeted CAR T-Cell Therapy.
Sylvain Lamure, Fran├žois Van Laethem, Delphine De Verbizier, Claire Lozano, Eve Gehlkopf, Jean-Jacques Tudesq, Chris Serrand, Mehdi Benzaoui, Tarik Kanouni, Adeline Quintard,[...]. Cancers (Basel) 2021
0

Improving CAR T-Cell Persistence.
Violena Pietrobon, Lauren Anne Todd, Anghsumala Goswami, Ofir Stefanson, Zhifen Yang, Francesco Marincola. Int J Mol Sci 2021
0

Advances and Challenges of CAR T Cells in Clinical Trials.
Astrid Holzinger, Hinrich Abken. Recent Results Cancer Res 2020
6

CAR T cells and checkpoint inhibition for the treatment of glioblastoma.
Steven H Shen, Karolina Woroniecka, Andrew B Barbour, Peter E Fecci, Luis Sanchez-Perez, John H Sampson. Expert Opin Biol Ther 2020
11

Single residue in CD28-costimulated CAR-T cells limits long-term persistence and antitumor durability.
Sonia Guedan, Aviv Madar, Victoria Casado-Medrano, Carolyn Shaw, Anna Wing, Fang Liu, Regina M Young, Carl H June, Avery D Posey. J Clin Invest 2020
39